Moreover, the number of enrolled patients with HR-positive, HER2-negative early breast cancer is high compared to that of other studies of the role of PET in the neoadjuvant setting, and, to our knowledge, this study is the first to establish the role of initial pSUVmax as a noninvasive predictive marker of pCR to NAC. Here, ERBB2 is linked to breast cancer.